Mays Cancer Center, University of Texas Health San Antonio, San Antonio, Texas.
Department of Molecular Immunology & Microbiology, University of Texas Health San Antonio, San Antonio, Texas.
Mol Cancer Ther. 2024 May 2;23(5):638-647. doi: 10.1158/1535-7163.MCT-23-0578.
Drug resistance is the major determinant for metastatic disease and fatalities, across all cancers. Depending on the tissue of origin and the therapeutic course, a variety of biological mechanisms can support and sustain drug resistance. Although genetic mutations and gene silencing through epigenetic mechanisms are major culprits in targeted therapy, drug efflux and polyploidization are more global mechanisms that prevail in a broad range of pathologies, in response to a variety of treatments. There is an unmet need to identify patients at risk for polyploidy, understand the mechanisms underlying polyploidization, and to develop strategies to predict, limit, and reverse polyploidy thus enhancing efficacy of standard-of-care therapy that improve better outcomes. This literature review provides an overview of polyploidy in cancer and offers perspective on patient monitoring and actionable therapy.
耐药性是所有癌症中导致转移疾病和死亡的主要决定因素。根据起源组织和治疗过程的不同,多种生物学机制可以支持和维持耐药性。虽然遗传突变和通过表观遗传机制的基因沉默是靶向治疗的主要罪魁祸首,但药物外排和多倍体化是更广泛的机制,广泛存在于多种病理中,以应对多种治疗方法。目前迫切需要确定具有多倍体风险的患者,了解多倍体化的机制,并制定预测、限制和逆转多倍体化的策略,从而提高改善预后的标准治疗的疗效。本文献综述概述了癌症中的多倍体化,并就患者监测和可行的治疗提供了观点。